tiprankstipranks
Trending News
More News >

Inozyme downgraded to Hold from Buy at Jefferies

Jefferies downgraded Inozyme (INZY) to Hold from Buy with a price target of $4, down from $15, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash. The firm believes INZ-701 fits into BioMarin’s enzyme treatment portfolio as a bolt-on, the analyst tells investors.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1